Sickle cell disease is the most common genetic blood disorder in the us, affecting between 90,000-100,000 people nationally and 4000-5000 in Illinois. The disease causes severe pain episodes that are unplanned, unpredictable, and reoccurring. Due to limited treatment options, patients are forced to seek treatment in costly emergency rooms to manage their pain. The University of Illinois at Chicago Sickle Cell Center is a regional leader in sickle cell treatment, delivering care to almost 1000 unique adult and pediatric sickle cell patients
Sickle cell disease is the most common genetic blood disorder in the us, affecting between 90,000-100,000 people nationally and 4000-5000 in Illinois. The disease causes severe pain episodes that are unplanned, unpredictable, and reoccurring. Due to limited treatment options, patients are forced to seek treatment in costly emergency rooms to manage their pain. The University of Illinois at Chicago Sickle Cell Center is a regional leader in sickle cell treatment, delivering care to almost 1000 unique adult and pediatric sickle cell patients
Sickle cell disease is the most common genetic blood disorder in the us, affecting between 90,000-100,000 people nationally and 4000-5000 in Illinois. The disease causes severe pain episodes that are unplanned, unpredictable, and reoccurring. Due to limited treatment options, patients are forced to seek treatment in costly emergency rooms to manage their pain. The University of Illinois at Chicago Sickle Cell Center is a regional leader in sickle cell treatment, delivering care to almost 1000 unique adult and pediatric sickle cell patients
Funding for UIC Sickle Cell Center on Chopping Block
Chicago, IL July 24, 2015 - Sickle cell disease is the most common genetic blood disorder in the US, affecting between 90,000-100,000 people nationally and 4000-5000 in Illinois. The disease causes changes in the shape of red blood cells that carry oxygen in the body, causing severe pain episodes that are unplanned, unpredictable, and reoccurring. Over the long term, sickle cell disease can result in kidney failure, cardiac function failure, pulmonary disease, bone disease, leg ulcers, and death. Due to limited treatment options, patients are forced to seek treatment in costly emergency rooms to manage their pain and are frequently admitted to the hospital. The University of Illinois at Chicago Sickle Cell Center is a regional leader in sickle cell treatment, delivering care to almost 1000 unique adult and pediatric sickle cell patients throughout the state. With funding from the state of Illinois, the Sickle Cell Center was able to open an acute care clinic that provided outpatient care to sickle cell patients that reduced the need for costly emergency room visits and hospitalizations. Despite the success of the Sickle Cell Center, state funding for the center has been eliminated in the proposed state budget. The UIC Sickle Cell Center Director, Dr. Victor Gordeuk states Further cuts to the Sickle Cell Center budget will be devastating, it will directly impact our ability to maintain the acute care infusion clinic and decrease the quality of care provided to sickle cell patients. Students form the University of Illinois College of Medicine are mounting a campaign urging state legislators to restore funding to the Sickle Cell Center. Additionally, the students are supporting HR0255, urging the Department of Health & Family Services to exempt sickle cell disease from the 30-day readmission rule. This will insure that hospitals receive the proper reimbursement necessary to provide a high level of care to sickle cell patients. For more information on the UIC Sickle Cell Center initiative, visit: http://
hpa432papsicklecell.weebly.com Contact: Adrian Boscolo-Hightower abosco4@uic.edu 808 S Wood St Chicago, IL 60612 TEL: 206-425-3877